Aintree University Hospital NHS Foundation Trust NCRI Hepatobiliary trials portfolio Hassan Z Malik MD, FRCS Consultant Hepatobiliary Surgeon
Number of NIHR studies available for recruiting patients each year 800 700 600 500 400 300 200 100 0 Total number of studies open to recruitment Non-commercial studies open to recruitment Commercial studies open to recruitment
Number of NIHR studies available for recruiting patients 713 cancer studies recruited patients since 1/4/15: 132 studies in rare cancers with ASR <3 225 studies in cancers with ASR <6 74 [or more] studies of cancer surgery 64 [or more] studies of radiotherapy 46 paediatric oncology studies 164 commercially sponsored studies
Remit of the HB sub-group • Hepatocellular carcinoma • Cholangiocarcinoma Our Aims : To improve outcomes for patients with HB cancer through progressive clinical trials and • Gallbladder carcinoma cutting edge translational research • Colorectal liver metastases* • CUP
The clinical problem of liver malignancy in the UK • There has been a 70% increase in HB malignancy which is now ranked 18 th in the UK • Colorectal cancer remains major problem with up to 50% patients developing liver dominant metastases Cancer registration statistics 2014 data – first release
Achievements of the group • Studies with published results: ABC-02, New EPOC, Photostent 2, ABC-03, and ABC-O4 • On going translational research in all closed • Closed studies and awaiting results: and currently recruiting studies. Links to 100,000 genome project BilCap and TACE2 • Studies in set-up: ACTTICA 1 and HTA - 13/153/04
The current portfolio map
How to get in involved • Information on the website: http://csg.ncri.org.uk/wp- content/uploads/2014/11NCRI-Upper-GI-CSG- AnnualReport-2014-15.pdf • Contact the chair of the group: hassan.malik@aintree.nhs.uk • Come to the annual trials meeting
BASO/NCRI meeting Liverpool 2016
Recommend
More recommend
